etodolac and Multiple Myeloma

etodolac has been researched along with Multiple Myeloma in 6 studies

Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.

Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

Research

Studies (6)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Duration of MRZ Treatment

Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.

Number of Cycles of Marizomib (MRZ)

(NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.

Number of Patients Exhibiting a Given Overall Response as Determined by Investigator

Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.

Number of Patients Receiving Marizomib (MRZ) in Each Cycle

A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.

Number of Patients With Treatment Emergent Adverse Events (TEAEs)

"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.

Number of Treatment Emergent Adverse Events (TEAEs)

"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.

Reviews

2 reviews available for etodolac and Multiple Myeloma

Other Studies

4 other studies available for etodolac and Multiple Myeloma